Drug intelligence / Profile preview

(E)-(S)-4-[(S)-4-methyl-2-((S)-3-methyl-2{(S)-2-[(5-methyl-isoxazole-3-carbonyl)-amino]-propionylamino}-butyrylamino)-pentanoylamino]-5-((S)-2-oxo-pyrrolidin-3-yl)-pent-2-enoic acid ethyl ester

Development stage
Unknown
Modality
Small Molecules
01

Overview

This compound is a synthetic small molecule with the molecular formula C30H46N6O8 and a molecular weight of approximately 618.7 g/mol[1][3][4]. It is listed in chemical databases such as PubChem and DrugBank under the identifier DB04710, but there is no evidence that it has been approved for clinical use or advanced beyond experimental status[1][3]. The structure contains an isoxazole moiety, multiple peptide-like amide bonds, and an ethyl ester functional group. No specific mechanism of action, biological target, or therapeutic indication has been described in public sources[1][3].

Other names
(E)-(S)-4-METHYL-2-( (S ) -3-METHYL - 2 { ( S ) - 2 - [ ( 5-METHYL - ISOXAZOLE - 3-CARBONYL ) - AMINO ] - PROPIONYLAMINO } - BUTYRYLAMINO ) - PENTANOYLAMINO ] –5– (( S ) – 2– OXO-PYRROLIDIN –3– YL) –PENT–2–ENOIC ACID ETHYL ESTER

Beyond the preview

Go deeper on (E)-(S)-4-[(S)-4-methyl-2-((S)-3-methyl-2{(S)-2-[(5-methyl-isoxazole-3-carbonyl)-amino]-propionylamino}-butyrylamino)-pentanoylamino]-5-((S)-2-oxo-pyrrolidin-3-yl)-pent-2-enoic acid ethyl ester.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on (E)-(S)-4-[(S)-4-methyl-2-((S)-3-methyl-2{(S)-2-[(5-methyl-isoxazole-3-carbonyl)-amino]-propionylamino}-butyrylamino)-pentanoylamino]-5-((S)-2-oxo-pyrrolidin-3-yl)-pent-2-enoic acid ethyl ester.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call